Abstract：Objective To investigate the clinical efficacy and safety of sacubitril/valsartan (LCZ696) on patients with acute myocardial infarction complicating heart failure. Methods We selected 120 patients with acute myocardial infarction complicating heart failure admitted in our hospital. Among them, 58 cases were treated with LCZ696 and conventional drugs as the intervention group while 62 cases only received conventional drug treatment as the control group. After 6 months of follow-up, the levels of NT-proBNP, creatinine and serum potassium, echocardiographic results, adverse reactions, major adverse cardiovascular events (MACEs), and quality of life were compared between the two groups before and after treatment. Results After treatment, the Minnesota living with heart failure questionnaire (MLHFQ) score, left ventricular end diastolic diameter (LVEDd) and NT-proBNP level in the intervention group and the control group are significantly lower than those before treatment; the above indexes in the intervention group are significantly lower than those in the control group (P<0.05). After treatment, left ventricular ejection fraction (LVEF) increases; LVEF of the intervention group is significantly higher than that of the control group (P<0.05). The rate of readmission due to heart failure and the MACEs incidence of the intervention group are significantly lower than those of the control group (P<0.05). The incidence of adverse reactions does not vary significantly between the two groups (P>0.05). After treatment, there is no significant increase in renal function creatinine and serum potassium levels (P>0.05). Conclusion For the patients with acute myocardial infarction complicating heart failure, LCZ696 is safe, reliable, and can improve the prognosis. It is worthy of being promoted in clinical practice.
